Company intelligence / Profile preview
FimmCyte
Basel, Basel-Stadt, Switzerlandfimmcyte.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
FimmCyte is a pre-clinical Swiss biotech developing non-hormonal, targeted immunotherapy (antibody-based) treatments for endometriosis and other fibro‑inflammatory diseases; its two lead multi-specific antibody assets are approaching IND-enabling/CMC activities for endometriosis and organ fibrosis, so no human clinical results have been reported yet.
- Therapeutic areas
- NephrologyOtherWomen's HealthCardiovascularRheumatology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
UZH Life Sciences Fund / University of Zurich (investment and support)
Beyond the preview
Go deeper on FimmCyte.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FimmCyte.